Related Experiment Videos
Limited cross-reactivity between different HIV-1 clades
Patience Mthunzi1, Debra Meyer
1Biochemistry Division, Department of Chemistry and Biochemistry, Rand Afrikaans University, P.O. Box 524, Auckland-Park 2006, Johannesburg, South Africa.
Summary
Researchers purified HIV envelope proteins from subtypes B/A and tested their reactivity with antibodies from subtype C infected patients. The study assessed cross-reactivity for potential vaccine development against diverse HIV strains.
Area of Science:
- Immunology
- Virology
- Vaccine Development
Background:
- Extensive research for an HIV/AIDS vaccine has focused on eliciting broadly neutralizing antibodies and cellular responses.
- Current HIV vaccine candidates primarily use envelope proteins from subtypes B/A, posing challenges for subtype C prevalent in developing nations.
- This study investigates cross-reactivity between different HIV subtypes to inform vaccine design.
Purpose of the Study:
- To purify recombinant HIV envelope proteins (gp120/140/160) from subtypes B/A using Galanthus nivalis affinity chromatography.
- To evaluate the reactivity of these purified proteins as antigens against antibodies from HIV-1 subtype C infected patients.
- To assess the functionality and immunogenicity of the purified proteins.
Main Methods:
- Galanthus nivalis affinity purification of recombinant HIV envelope proteins (CHO gp120/140/160) from subtypes B/A.
- Enzyme-Linked Immunosorbent Assay (ELISA) to detect antibody titers against purified antigens.
- Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and N-terminal sequencing for protein identity confirmation.
- Apoptosis assays to confirm protein functionality.
- Immunization of mice with purified proteins to elicit polyclonal antibodies.
Main Results:
- Polyclonal antibodies from HIV-1 subtype C infected patients recognized the purified subtype B/A antigens with varying titers (100-1000).
- Purified proteins were confirmed for identity and functionality (apoptosis induction).
- Antibodies elicited in mice against the immunogens showed high reactivity (500-5000 titers) and cross-reactivity at lower titers.
Conclusions:
- Recombinant HIV envelope proteins from subtypes B/A can be recognized by antibodies from subtype C infected individuals.
- The purified proteins demonstrate functionality and immunogenicity, eliciting cross-reactive antibodies.
- Findings support the potential for developing vaccines that target conserved epitopes across different HIV subtypes.